Table 3.
Sensitivity analysis including TT dispensed at hospitals: estimated mean costs, mean survival, estimated LYG, and cost per LYG per patient in Swedish patients with mRCC by period of diagnosis
| Outcomes | Estimates by cohort | Pairwise cohort comparisons | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| PreTT (2002–2005) n=1,466 | TTi (2006–2008) n=1,158 | TTii (2009–2010) n=806 | TTi vs PreTT | TTii vs PreTT | TTii vs TTi | |
|
| ||||||
| Costs, $ | ||||||
| Inpatient costs | 9,978 | 10,948 | 9,503 | 970 | −475 | −1,445 |
| Outpatient costs | 2,802 | 3,157 | 2,794 | 356 | −8 | −363 |
| Other drug costs | 2,898 | 4,001 | 3,682 | 1,103 | 784 | −319 |
| TT costs | 1,563 | 16,223 | 20,244 | 14,661 | 18,681 | 4,021 |
| Total costs | 17,240 | 34,329 | 36,223 | 17,089 | 18,982 | 1,894 |
| Mean survival, years | 1.45 | 1.62 | 1.83 | |||
| LYG | 0.17 | 0.39 | 0.22 | |||
| Cost per LYG, $ | 103,171 | 49,297 | 8,629 | |||
Notes: All costs are presented in US$.
Abbreviations: LYG, life-years gained; mRCC, metastatic renal cell carcinoma; PreTT, pre-TT introduction (patients diagnosed with mRCC 2002–2005); TT, targeted therapies; TTi, early TT introduction (patients diagnosed with mRCC 2006–2008); TTii, late TT introduction (patients diagnosed with mRCC 2009–2010).